{"gene":"TTBK1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2006,"finding":"TTBK1 is a serine/threonine/tyrosine kinase belonging to the casein kinase 1 superfamily that directly phosphorylates tau protein at Ser198, Ser199, Ser202, and Ser422 in a Mg2+- and Mn2+-dependent manner, and induces tau aggregation in human neuronal cells in a dose-dependent manner.","method":"In vitro kinase assay with phosphopeptide mapping and immunoblotting; overexpression in human neuronal cells","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with phosphopeptide mapping and site-specific immunoblotting; replicated by multiple subsequent studies","pmids":["16923168"],"is_preprint":false},{"year":2006,"finding":"TTBK1 is specifically expressed in the brain, particularly in the cytoplasm of cortical and hippocampal neurons, and is conserved among species.","method":"Subcellular fractionation and immunohistochemistry of brain tissue","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — localization determined by fractionation/IHC in a single study; replicated in subsequent work","pmids":["16923168"],"is_preprint":false},{"year":2014,"finding":"TTBK1 directly phosphorylates TDP-43 in vitro and promotes TDP-43 phosphorylation in mammalian cultured cells; TTBK1 overexpression drives relocalization of TDP-43 from the nucleus to cytoplasmic inclusions resembling neuropathological aggregates.","method":"In vitro kinase assay; overexpression in mammalian cells with immunofluorescence; C. elegans kinome-wide screen for TDP-43 phosphorylation modifiers","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro direct phosphorylation assay plus cell-based relocalization confirmed in two model systems; replicated in subsequent studies","pmids":["25473830"],"is_preprint":false},{"year":2018,"finding":"In C. elegans transgenic models, co-expression of TTBK1 with tau or TDP-43 causes synergistic exacerbation of behavioral abnormalities, increased pathological protein phosphorylation, aberrant neuronal architecture, and neuron loss, establishing a pathway-level role for TTBK1 upstream of tau and TDP-43 toxicity.","method":"Genetic epistasis via C. elegans transgenic co-expression; behavioral assays; neuronal morphology analysis","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in whole-organism model with multiple orthogonal phenotypic readouts; consistent with prior in vitro phosphorylation data","pmids":["29409526"],"is_preprint":false},{"year":2018,"finding":"In Drosophila, TTBK1 expression alone causes neuronal toxicity, and co-expression with human Tau exacerbates this toxicity more strongly than TTBK2 or MARK1, suggesting TTBK1-Tau combinatorial toxicity may occur through independent mechanisms rather than solely direct tau phosphorylation.","method":"Drosophila transgenic co-expression; lifespan and locomotor analysis; mutagenesis and phosphorylation analysis","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in Drosophila with mutagenesis, single lab","pmids":["28711868"],"is_preprint":false},{"year":2020,"finding":"TTBK1 regulates tau phosphorylation in heterologous cells and primary neurons; TTBK1-specific phosphorylation of tau leads to decreased tau-tubulin binding and deficits in tubulin polymerization, representing a loss of normal tau function.","method":"Overexpression and knockdown in heterologous cells and primary neurons; tubulin polymerization assay; selective small molecule inhibitor (BIIB-TTBK1i) in vivo","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (KD/OE, functional polymerization assay, selective inhibitor in vivo) in a single study; consistent with prior work","pmids":["32255788"],"is_preprint":false},{"year":2021,"finding":"Structural analysis of the TTBK1 kinase domain bound to an NIK inhibitor enabled structure-guided design of selective TTBK1 inhibitors; pharmacological TTBK1 inhibition in vivo (mouse and rat) significantly lowers tau phosphorylation at Ser422.","method":"Structural analysis (kinase domain co-crystal); medicinal chemistry optimization; in vivo pharmacology in mouse hypothermia and rat developmental models","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of kinase domain plus in vivo target engagement confirmed by phospho-tau reduction","pmids":["33944571"],"is_preprint":false},{"year":2023,"finding":"TTBK1 inhibition (using selective chemical tools) reduces TDP-43 phosphorylation and restores nuclear TDP-43 localization in lymphoblasts from Alzheimer's disease patients, and conditioned medium from TTBK1-inhibitor-treated AD lymphoblasts fails to propagate TDP-43 pathology to control cells.","method":"Chemical inhibitor treatment of patient-derived immortalized lymphocytes; western blot for TDP-43 phosphorylation and localization; conditioned medium disease propagation assay","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective inhibitor in human-derived cells with multiple readouts, single lab","pmids":["37621404"],"is_preprint":false},{"year":2018,"finding":"TTBK1 is identified as a member of a distinct kinase family (casein kinase 1 superfamily) with documented substrates tau, tubulin, and TDP-43, and shows brain-enriched expression distinct from TTBK2; review also notes involvement in neurotransmission-related phosphorylation pathways.","method":"Review/synthesis of published experimental data","journal":"European journal of medicinal chemistry","confidence":"Low","confidence_rationale":"Tier 4 / Weak — review paper synthesizing prior experimental findings, no new experiments","pmids":["30342424"],"is_preprint":false}],"current_model":"TTBK1 is a neuron-enriched serine/threonine/tyrosine kinase of the casein kinase 1 superfamily that directly phosphorylates tau at AD-relevant sites (Ser198, Ser199, Ser202, Ser422) in a Mg2+/Mn2+-dependent manner, reducing tau-tubulin binding and impairing tubulin polymerization, and also directly phosphorylates TDP-43, driving its relocalization from the nucleus to cytoplasmic inclusions; genetic epistasis in C. elegans and Drosophila, combined with selective small-molecule inhibitor studies in rodents and patient-derived cells, establishes TTBK1 as an upstream kinase whose activity promotes tau aggregation, TDP-43 proteinopathy, and neurodegeneration."},"narrative":{"mechanistic_narrative":"TTBK1 is a brain-enriched serine/threonine/tyrosine kinase of the casein kinase 1 superfamily that acts as an upstream driver of two distinct neurodegenerative proteinopathies [PMID:16923168, PMID:25473830]. It directly phosphorylates tau at Ser198, Ser199, Ser202, and Ser422 in a Mg2+/Mn2+-dependent manner, inducing dose-dependent tau aggregation in human neuronal cells [PMID:16923168]; this phosphorylation decreases tau-tubulin binding and impairs tubulin polymerization, representing a loss of normal tau function alongside the gain of aggregation propensity [PMID:32255788]. In parallel, TTBK1 directly phosphorylates TDP-43 and drives its relocalization from the nucleus to cytoplasmic inclusions resembling neuropathological aggregates [PMID:25473830]. Genetic epistasis in C. elegans and Drosophila places TTBK1 upstream of both tau and TDP-43 toxicity, where co-expression synergistically exacerbates pathological phosphorylation, aberrant neuronal architecture, and neuron loss [PMID:29409526, PMID:28711868]. Structure-guided selective inhibitors engage TTBK1 in vivo to lower tau phosphorylation at Ser422 [PMID:33944571], and inhibition in Alzheimer's disease patient-derived lymphoblasts reduces TDP-43 phosphorylation, restores nuclear TDP-43, and blocks propagation of TDP-43 pathology [PMID:37621404].","teleology":[{"year":2006,"claim":"Establishing that a then-uncharacterized brain kinase could directly modify tau answered whether TTBK1 is a bona fide tau kinase and linked it to a candidate disease mechanism.","evidence":"In vitro kinase assay with phosphopeptide mapping and overexpression in human neuronal cells; subcellular fractionation and IHC of brain tissue","pmids":["16923168"],"confidence":"High","gaps":["Did not establish whether endogenous TTBK1 phosphorylates tau in neurons","Physiological substrate beyond tau not defined","Regulation of kinase activity unknown"]},{"year":2014,"claim":"Identifying TDP-43 as a second direct substrate showed TTBK1 is not tau-specific and connected it to TDP-43 proteinopathy via nuclear-to-cytoplasmic mislocalization.","evidence":"In vitro kinase assay, overexpression with immunofluorescence in mammalian cells, and C. elegans kinome-wide screen","pmids":["25473830"],"confidence":"High","gaps":["TDP-43 phosphosites driving relocalization not mapped","Whether mislocalization is direct consequence of phosphorylation versus secondary not resolved"]},{"year":2018,"claim":"Whole-organism genetic epistasis tested whether TTBK1 acts upstream of tau and TDP-43 toxicity rather than merely phosphorylating them in vitro, establishing a pathway-level role.","evidence":"C. elegans and Drosophila transgenic co-expression with behavioral, locomotor, and neuronal morphology readouts plus mutagenesis","pmids":["29409526","28711868"],"confidence":"High","gaps":["Drosophila data raise that TTBK1-tau toxicity may act through mechanisms independent of direct tau phosphorylation","Mammalian in vivo confirmation of epistasis not provided"]},{"year":2020,"claim":"Defining the functional consequence of TTBK1-specific tau phosphorylation answered what cellular deficit it produces, showing reduced tau-tubulin binding and impaired tubulin polymerization.","evidence":"Knockdown/overexpression in heterologous cells and primary neurons, tubulin polymerization assay, and selective inhibitor in vivo","pmids":["32255788"],"confidence":"High","gaps":["Link between loss of tau function and downstream neurodegeneration not directly demonstrated","Endogenous regulation of TTBK1 in neurons not addressed"]},{"year":2021,"claim":"A kinase-domain co-crystal structure enabled selective inhibitor design and demonstrated in vivo target engagement, converting TTBK1 from a candidate into a druggable target.","evidence":"Co-crystal structure of the kinase domain, medicinal chemistry optimization, and in vivo pharmacology in mouse and rat models measuring phospho-tau Ser422","pmids":["33944571"],"confidence":"High","gaps":["Structure of full-length protein or substrate-bound complex not determined","Mechanism of substrate recognition not defined"]},{"year":2023,"claim":"Testing selective inhibition in patient-derived cells assessed disease relevance, showing TTBK1 inhibition reverses TDP-43 mislocalization and blocks pathology propagation in Alzheimer's disease lymphoblasts.","evidence":"Chemical inhibitor treatment of AD patient-derived immortalized lymphocytes, western blot for TDP-43 phosphorylation/localization, and conditioned-medium propagation assay","pmids":["37621404"],"confidence":"Medium","gaps":["Single lab and non-neuronal cell type (lymphoblasts)","Mechanism of conditioned-medium propagation and the propagating species not identified"]},{"year":null,"claim":"How endogenous TTBK1 activity is regulated and what controls its substrate selection between tau and TDP-43 in neurons remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["Upstream regulators and activation signals of TTBK1 unknown","Determinants of tau-versus-TDP-43 substrate choice undefined","No direct mammalian in vivo demonstration that TTBK1 inhibition prevents neurodegeneration"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,5]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,7]}],"complexes":[],"partners":["MAPT","TARDBP","TUBB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q5TCY1","full_name":"Tau-tubulin kinase 1","aliases":["Brain-derived tau kinase"],"length_aa":1321,"mass_kda":142.7,"function":"Serine/threonine kinase which is able to phosphorylate TAU on serine, threonine and tyrosine residues. Induces aggregation of TAU","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q5TCY1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TTBK1","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TTBK1","total_profiled":1310},"omim":[{"mim_id":"619415","title":"TAU TUBULIN KINASE 1; TTBK1","url":"https://www.omim.org/entry/619415"},{"mim_id":"611695","title":"TAU TUBULIN KINASE 2; TTBK2","url":"https://www.omim.org/entry/611695"},{"mim_id":"605078","title":"TAR DNA-BINDING PROTEIN; TARDBP","url":"https://www.omim.org/entry/605078"},{"mim_id":"157140","title":"MICROTUBULE-ASSOCIATED PROTEIN TAU; MAPT","url":"https://www.omim.org/entry/157140"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":14.5},{"tissue":"pituitary gland","ntpm":7.2}],"url":"https://www.proteinatlas.org/search/TTBK1"},"hgnc":{"alias_symbol":["KIAA1855"],"prev_symbol":[]},"alphafold":{"accession":"Q5TCY1","domains":[{"cath_id":"3.30.200.20","chopping":"35-110","consensus_level":"medium","plddt":95.303,"start":35,"end":110},{"cath_id":"1.10.510.10","chopping":"113-310","consensus_level":"medium","plddt":97.3397,"start":113,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5TCY1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5TCY1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5TCY1-F1-predicted_aligned_error_v6.png","plddt_mean":51.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TTBK1","jax_strain_url":"https://www.jax.org/strain/search?query=TTBK1"},"sequence":{"accession":"Q5TCY1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5TCY1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5TCY1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5TCY1"}},"corpus_meta":[{"pmid":"16923168","id":"PMC_16923168","title":"Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.","date":"2006","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16923168","citation_count":117,"is_preprint":false},{"pmid":"25473830","id":"PMC_25473830","title":"The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25473830","citation_count":103,"is_preprint":false},{"pmid":"29409526","id":"PMC_29409526","title":"Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29409526","citation_count":79,"is_preprint":false},{"pmid":"30556160","id":"PMC_30556160","title":"miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30556160","citation_count":47,"is_preprint":false},{"pmid":"32891070","id":"PMC_32891070","title":"Long non-coding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer's disease.","date":"2020","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32891070","citation_count":46,"is_preprint":false},{"pmid":"30342424","id":"PMC_30342424","title":"Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30342424","citation_count":38,"is_preprint":false},{"pmid":"33944571","id":"PMC_33944571","title":"Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33944571","citation_count":22,"is_preprint":false},{"pmid":"32255788","id":"PMC_32255788","title":"Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32255788","citation_count":20,"is_preprint":false},{"pmid":"37059819","id":"PMC_37059819","title":"Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37059819","citation_count":17,"is_preprint":false},{"pmid":"28711868","id":"PMC_28711868","title":"Human TTBK1, TTBK2 and MARK1 kinase toxicity in Drosophila melanogaster is exacerbated by co-expression of human Tau.","date":"2017","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/28711868","citation_count":14,"is_preprint":false},{"pmid":"37621404","id":"PMC_37621404","title":"TTBK1 and CK1 inhibitors restore TDP-43 pathology and avoid disease propagation in lymphoblast from Alzheimer's disease patients.","date":"2023","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37621404","citation_count":13,"is_preprint":false},{"pmid":"38536493","id":"PMC_38536493","title":"Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.","date":"2024","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38536493","citation_count":8,"is_preprint":false},{"pmid":"39892471","id":"PMC_39892471","title":"Enriched environment mitigates cognitive impairment in pre-adolescent mice following repeated neonatal sevoflurane exposure by reducing TTBK1 expression and Tau phosphorylation.","date":"2025","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39892471","citation_count":7,"is_preprint":false},{"pmid":"39050776","id":"PMC_39050776","title":"Computational identification of potential tau tubulin kinase 1 (TTBK1) inhibitors: a structural analog approach.","date":"2024","source":"In silico pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39050776","citation_count":1,"is_preprint":false},{"pmid":"39953251","id":"PMC_39953251","title":"Environmental enrichment attenuates sevoflurane anesthesia-induced learning deficits in aged mice through regulating TTBK1 and phosphorylated Tau expression.","date":"2025","source":"Experimental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/39953251","citation_count":0,"is_preprint":false},{"pmid":"40598720","id":"PMC_40598720","title":"A Multiscale Computational Study for the Identification of Novel Inhibitors Targeting Tau-Tubulin Kinase 1 (TTBK1) in Alzheimer's Disease.","date":"2025","source":"Current computer-aided drug design","url":"https://pubmed.ncbi.nlm.nih.gov/40598720","citation_count":0,"is_preprint":false},{"pmid":"41545183","id":"PMC_41545183","title":"Biallelic TTBK1 variant causes a severe syndromic neurodevelopmental disorder: clinical and genetic insights from two siblings.","date":"2026","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41545183","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11125,"output_tokens":2124,"usd":0.032618,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9176,"output_tokens":2432,"usd":0.05334,"stage2_stop_reason":"end_turn"},"total_usd":0.085958,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"TTBK1 is a serine/threonine/tyrosine kinase belonging to the casein kinase 1 superfamily that directly phosphorylates tau protein at Ser198, Ser199, Ser202, and Ser422 in a Mg2+- and Mn2+-dependent manner, and induces tau aggregation in human neuronal cells in a dose-dependent manner.\",\n      \"method\": \"In vitro kinase assay with phosphopeptide mapping and immunoblotting; overexpression in human neuronal cells\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with phosphopeptide mapping and site-specific immunoblotting; replicated by multiple subsequent studies\",\n      \"pmids\": [\"16923168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TTBK1 is specifically expressed in the brain, particularly in the cytoplasm of cortical and hippocampal neurons, and is conserved among species.\",\n      \"method\": \"Subcellular fractionation and immunohistochemistry of brain tissue\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — localization determined by fractionation/IHC in a single study; replicated in subsequent work\",\n      \"pmids\": [\"16923168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TTBK1 directly phosphorylates TDP-43 in vitro and promotes TDP-43 phosphorylation in mammalian cultured cells; TTBK1 overexpression drives relocalization of TDP-43 from the nucleus to cytoplasmic inclusions resembling neuropathological aggregates.\",\n      \"method\": \"In vitro kinase assay; overexpression in mammalian cells with immunofluorescence; C. elegans kinome-wide screen for TDP-43 phosphorylation modifiers\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro direct phosphorylation assay plus cell-based relocalization confirmed in two model systems; replicated in subsequent studies\",\n      \"pmids\": [\"25473830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In C. elegans transgenic models, co-expression of TTBK1 with tau or TDP-43 causes synergistic exacerbation of behavioral abnormalities, increased pathological protein phosphorylation, aberrant neuronal architecture, and neuron loss, establishing a pathway-level role for TTBK1 upstream of tau and TDP-43 toxicity.\",\n      \"method\": \"Genetic epistasis via C. elegans transgenic co-expression; behavioral assays; neuronal morphology analysis\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in whole-organism model with multiple orthogonal phenotypic readouts; consistent with prior in vitro phosphorylation data\",\n      \"pmids\": [\"29409526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Drosophila, TTBK1 expression alone causes neuronal toxicity, and co-expression with human Tau exacerbates this toxicity more strongly than TTBK2 or MARK1, suggesting TTBK1-Tau combinatorial toxicity may occur through independent mechanisms rather than solely direct tau phosphorylation.\",\n      \"method\": \"Drosophila transgenic co-expression; lifespan and locomotor analysis; mutagenesis and phosphorylation analysis\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in Drosophila with mutagenesis, single lab\",\n      \"pmids\": [\"28711868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TTBK1 regulates tau phosphorylation in heterologous cells and primary neurons; TTBK1-specific phosphorylation of tau leads to decreased tau-tubulin binding and deficits in tubulin polymerization, representing a loss of normal tau function.\",\n      \"method\": \"Overexpression and knockdown in heterologous cells and primary neurons; tubulin polymerization assay; selective small molecule inhibitor (BIIB-TTBK1i) in vivo\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (KD/OE, functional polymerization assay, selective inhibitor in vivo) in a single study; consistent with prior work\",\n      \"pmids\": [\"32255788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Structural analysis of the TTBK1 kinase domain bound to an NIK inhibitor enabled structure-guided design of selective TTBK1 inhibitors; pharmacological TTBK1 inhibition in vivo (mouse and rat) significantly lowers tau phosphorylation at Ser422.\",\n      \"method\": \"Structural analysis (kinase domain co-crystal); medicinal chemistry optimization; in vivo pharmacology in mouse hypothermia and rat developmental models\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of kinase domain plus in vivo target engagement confirmed by phospho-tau reduction\",\n      \"pmids\": [\"33944571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TTBK1 inhibition (using selective chemical tools) reduces TDP-43 phosphorylation and restores nuclear TDP-43 localization in lymphoblasts from Alzheimer's disease patients, and conditioned medium from TTBK1-inhibitor-treated AD lymphoblasts fails to propagate TDP-43 pathology to control cells.\",\n      \"method\": \"Chemical inhibitor treatment of patient-derived immortalized lymphocytes; western blot for TDP-43 phosphorylation and localization; conditioned medium disease propagation assay\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective inhibitor in human-derived cells with multiple readouts, single lab\",\n      \"pmids\": [\"37621404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TTBK1 is identified as a member of a distinct kinase family (casein kinase 1 superfamily) with documented substrates tau, tubulin, and TDP-43, and shows brain-enriched expression distinct from TTBK2; review also notes involvement in neurotransmission-related phosphorylation pathways.\",\n      \"method\": \"Review/synthesis of published experimental data\",\n      \"journal\": \"European journal of medicinal chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — review paper synthesizing prior experimental findings, no new experiments\",\n      \"pmids\": [\"30342424\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TTBK1 is a neuron-enriched serine/threonine/tyrosine kinase of the casein kinase 1 superfamily that directly phosphorylates tau at AD-relevant sites (Ser198, Ser199, Ser202, Ser422) in a Mg2+/Mn2+-dependent manner, reducing tau-tubulin binding and impairing tubulin polymerization, and also directly phosphorylates TDP-43, driving its relocalization from the nucleus to cytoplasmic inclusions; genetic epistasis in C. elegans and Drosophila, combined with selective small-molecule inhibitor studies in rodents and patient-derived cells, establishes TTBK1 as an upstream kinase whose activity promotes tau aggregation, TDP-43 proteinopathy, and neurodegeneration.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TTBK1 is a brain-enriched serine/threonine/tyrosine kinase of the casein kinase 1 superfamily that acts as an upstream driver of two distinct neurodegenerative proteinopathies [#0, #2]. It directly phosphorylates tau at Ser198, Ser199, Ser202, and Ser422 in a Mg2+/Mn2+-dependent manner, inducing dose-dependent tau aggregation in human neuronal cells [#0]; this phosphorylation decreases tau-tubulin binding and impairs tubulin polymerization, representing a loss of normal tau function alongside the gain of aggregation propensity [#5]. In parallel, TTBK1 directly phosphorylates TDP-43 and drives its relocalization from the nucleus to cytoplasmic inclusions resembling neuropathological aggregates [#2]. Genetic epistasis in C. elegans and Drosophila places TTBK1 upstream of both tau and TDP-43 toxicity, where co-expression synergistically exacerbates pathological phosphorylation, aberrant neuronal architecture, and neuron loss [#3, #4]. Structure-guided selective inhibitors engage TTBK1 in vivo to lower tau phosphorylation at Ser422 [#6], and inhibition in Alzheimer's disease patient-derived lymphoblasts reduces TDP-43 phosphorylation, restores nuclear TDP-43, and blocks propagation of TDP-43 pathology [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that a then-uncharacterized brain kinase could directly modify tau answered whether TTBK1 is a bona fide tau kinase and linked it to a candidate disease mechanism.\",\n      \"evidence\": \"In vitro kinase assay with phosphopeptide mapping and overexpression in human neuronal cells; subcellular fractionation and IHC of brain tissue\",\n      \"pmids\": [\"16923168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether endogenous TTBK1 phosphorylates tau in neurons\", \"Physiological substrate beyond tau not defined\", \"Regulation of kinase activity unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying TDP-43 as a second direct substrate showed TTBK1 is not tau-specific and connected it to TDP-43 proteinopathy via nuclear-to-cytoplasmic mislocalization.\",\n      \"evidence\": \"In vitro kinase assay, overexpression with immunofluorescence in mammalian cells, and C. elegans kinome-wide screen\",\n      \"pmids\": [\"25473830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TDP-43 phosphosites driving relocalization not mapped\", \"Whether mislocalization is direct consequence of phosphorylation versus secondary not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Whole-organism genetic epistasis tested whether TTBK1 acts upstream of tau and TDP-43 toxicity rather than merely phosphorylating them in vitro, establishing a pathway-level role.\",\n      \"evidence\": \"C. elegans and Drosophila transgenic co-expression with behavioral, locomotor, and neuronal morphology readouts plus mutagenesis\",\n      \"pmids\": [\"29409526\", \"28711868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Drosophila data raise that TTBK1-tau toxicity may act through mechanisms independent of direct tau phosphorylation\", \"Mammalian in vivo confirmation of epistasis not provided\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defining the functional consequence of TTBK1-specific tau phosphorylation answered what cellular deficit it produces, showing reduced tau-tubulin binding and impaired tubulin polymerization.\",\n      \"evidence\": \"Knockdown/overexpression in heterologous cells and primary neurons, tubulin polymerization assay, and selective inhibitor in vivo\",\n      \"pmids\": [\"32255788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between loss of tau function and downstream neurodegeneration not directly demonstrated\", \"Endogenous regulation of TTBK1 in neurons not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A kinase-domain co-crystal structure enabled selective inhibitor design and demonstrated in vivo target engagement, converting TTBK1 from a candidate into a druggable target.\",\n      \"evidence\": \"Co-crystal structure of the kinase domain, medicinal chemistry optimization, and in vivo pharmacology in mouse and rat models measuring phospho-tau Ser422\",\n      \"pmids\": [\"33944571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length protein or substrate-bound complex not determined\", \"Mechanism of substrate recognition not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Testing selective inhibition in patient-derived cells assessed disease relevance, showing TTBK1 inhibition reverses TDP-43 mislocalization and blocks pathology propagation in Alzheimer's disease lymphoblasts.\",\n      \"evidence\": \"Chemical inhibitor treatment of AD patient-derived immortalized lymphocytes, western blot for TDP-43 phosphorylation/localization, and conditioned-medium propagation assay\",\n      \"pmids\": [\"37621404\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab and non-neuronal cell type (lymphoblasts)\", \"Mechanism of conditioned-medium propagation and the propagating species not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How endogenous TTBK1 activity is regulated and what controls its substrate selection between tau and TDP-43 in neurons remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Upstream regulators and activation signals of TTBK1 unknown\", \"Determinants of tau-versus-TDP-43 substrate choice undefined\", \"No direct mammalian in vivo demonstration that TTBK1 inhibition prevents neurodegeneration\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAPT\", \"TARDBP\", \"TUBB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}